Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4905417 in saphenous vein graft disease prevention after CABG
NCT01245634Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2010
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of inclacumab in saphenous vein graft disease (SVGD), sponsored by Roche. Started Dec 2010; status: completed.
02
Drugs
inclacumab
03
Conditions
saphenous vein graft disease (SVGD)
Beyond the preview
Go deeper on NCT01245634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245634.